Literature DB >> 24806509

Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in Klinefelter syndrome.

Vikram V Shanbhogue1, Stinus Hansen, Niklas Rye Jørgensen, Kim Brixen, Claus H Gravholt.   

Abstract

Although the expected skeletal manifestations of testosterone deficiency in Klinefelter's syndrome (KS) are osteopenia and osteoporosis, the structural basis for this is unclear. The aim of this study was to assess bone geometry, volumetric bone mineral density (vBMD), microarchitecture, and estimated bone strength using high-resolution peripheral quantitative computed tomography (HR-pQCT) in patients with KS. Thirty-one patients with KS confirmed by lymphocyte chromosome karyotyping aged 35.8 ± 8.2 years were recruited consecutively from a KS outpatient clinic and matched with respect to age and height with 31 healthy subjects aged 35.9 ± 8.2 years. Dual-energy X-ray absorptiometry (DXA) and HR-pQCT were performed in all participants, and blood samples were analyzed for hormonal status and bone biomarkers in KS patients. Twenty-one KS patients were on long-term testosterone-replacement therapy. In weight-adjusted models, HR-pQCT revealed a significantly lower cortical area (p < 0.01), total and trabecular vBMD (p = 0.02 and p = 0.04), trabecular bone volume fraction (p = 0.04), trabecular number (p = 0.05), and estimates of bone strength, whereas trabecular spacing was higher (p = 0.03) at the tibia in KS patients. In addition, cortical thickness was significantly reduced, both at the radius and tibia (both p < 0.01). There were no significant differences in indices of bone structure, estimated bone strength, or bone biomarkers in KS patients with and without testosterone therapy. This study showed that KS patients had lower total vBMD and a compromised trabecular compartment with a reduced trabecular density and bone volume fraction at the tibia. The compromised trabecular network integrity attributable to a lower trabecular number with relative preservation of trabecular thickness is similar to the picture found in women with aging. KS patients also displayed a reduced cortical area and thickness at the tibia, which in combination with the trabecular deficits, compromised estimated bone strength at this site.
© 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  FINITE ELEMENT ANALYSIS; HR-pQCT; KLINEFELTER SYNDROME; TRABECULAR NUMBER; vBMD

Mesh:

Substances:

Year:  2014        PMID: 24806509     DOI: 10.1002/jbmr.2272

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  12 in total

1.  Relative hyperestrogenism in Klinefelter Syndrome: results from a meta-analysis.

Authors:  Daniele Santi; Sara De Vincentis; Sara Scaltriti; Vincenzo Rochira
Journal:  Endocrine       Date:  2019-01-30       Impact factor: 3.633

Review 2.  Morbidity in Klinefelter syndrome and the effect of testosterone treatment.

Authors:  Simon Chang; Anne Skakkebaek; Shanlee M Davis; Claus H Gravholt
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-06-04       Impact factor: 3.908

3.  Body composition, trabecular bone score and vertebral fractures in subjects with Klinefelter syndrome.

Authors:  W Vena; F Carrone; G Mazziotti; A Ferlin; A Delbarba; O Akpojiyovbi; L C Pezzaioli; P Facondo; C Cappelli; L Leonardi; L Balzarini; D Farina; A Pizzocaro; A G Lania
Journal:  J Endocrinol Invest       Date:  2022-08-28       Impact factor: 5.467

4.  Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.

Authors:  A Nordenström; S F Ahmed; E van den Akker; J Blair; M Bonomi; C Brachet; L H A Broersen; H L Claahsen-van der Grinten; A B Dessens; A Gawlik; C H Gravholt; A Juul; C Krausz; T Raivio; A Smyth; P Touraine; D Vitali; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

5.  Klinefelter Bone Microarchitecture Evolution with Testosterone Replacement Therapy.

Authors:  A Piot; I Plotton; S Boutroy; J Bacchetta; S Ailloud; H Lejeune; R D Chapurlat; P Szulc; C B Confavreux
Journal:  Calcif Tissue Int       Date:  2022-02-13       Impact factor: 4.000

6.  Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome.

Authors:  N Tahani; L Nieddu; G Prossomariti; M Spaziani; S Granato; F Carlomagno; A Anzuini; A Lenzi; A F Radicioni; E Romagnoli
Journal:  Endocrine       Date:  2018-04-25       Impact factor: 3.633

7.  Bone Mineral Status in Children and Adolescents with Klinefelter Syndrome.

Authors:  Stefano Stagi; Mariarosaria Di Tommaso; Cristina Manoni; Perla Scalini; Francesco Chiarelli; Alberto Verrotti; Elisabetta Lapi; Sabrina Giglio; Laura Dosa; Maurizio de Martino
Journal:  Int J Endocrinol       Date:  2016-06-16       Impact factor: 3.257

Review 8.  Male Hypogonadism and Osteoporosis: The Effects, Clinical Consequences, and Treatment of Testosterone Deficiency in Bone Health.

Authors:  Gary Golds; Devon Houdek; Terra Arnason
Journal:  Int J Endocrinol       Date:  2017-03-16       Impact factor: 3.257

9.  Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone.

Authors:  Husam Ghanim; Sandeep Dhindsa; Kelly Green; Sanaa Abuaysheh; Manav Batra; Antoine Makdissi; Ajay Chaudhuri; Paresh Dandona
Journal:  J Endocr Soc       Date:  2019-07-01

10.  Evaluation of the Efficacy of Transdermal and Injection Testosterone Therapy in Klinefelter Syndrome: A Real-Life Study.

Authors:  Apiraa Kabilan; Anne Skakkebæk; Simon Chang; Claus H Gravholt
Journal:  J Endocr Soc       Date:  2021-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.